The International Journal of Hypertension, published by HINDAWI LTD, is a pivotal open-access journal dedicated to advancing knowledge in the field of hypertension and cardiovascular health. Since its inception in 2010, the journal has provided a vital platform for researchers, clinicians, and students to disseminate innovative findings and comprehensive reviews spanning various aspects of hypertension management, pathophysiology, and epidemiology. Residing in Q3 of the Internal Medicine category and ranked 75 out of 167 in the Scopus rankings, it reflects a commitment to quality and relevance in medical research. With a global reach, the journal aims to foster collaboration and knowledge exchange, contributing significantly to the scientific community's efforts to combat hypertension-related health issues. Accessible since 2010, this journal exemplifies the principles of open science, ensuring that critical research is available to all stakeholders in the field.

Clinical and Experimental Hypertension, published by Taylor & Francis Inc, is a crucial resource in the fields of internal medicine and physiology. With its inaugural publication dating back to 1978, this esteemed journal has successfully merged decades of research, providing a platform for the latest advancements in hypertension studies. Operating without an open access model, it is configured to serve a specialized audience of researchers, clinicians, and students who are dedicated to exploring innovative treatment modalities and understanding the complexities of hypertensive diseases. Ranked in the Q3 category in both Internal Medicine and Physiology, this journal accomplishes a commendable standing in the academic community, exemplified by its Scopus rankings which position it within the median percentile range in its field. By disseminating high-quality research and fostering scientific dialogue, Clinical and Experimental Hypertension plays a pivotal role in shaping contemporary understanding and clinical practices concerning hypertension management.

Chronic Obstructive Pulmonary Diseases - Journal of the COPD Foundation, published by the esteemed COPD Foundation, serves as a vital platform for advancing research in the field of pulmonary and respiratory medicine. With an ISSN of 2372-952X, this journal emphasizes the exploration and dissemination of knowledge related to chronic obstructive pulmonary disease (COPD) while addressing broader topics in respiratory health. Recognized within the Q2 category of the 2023 *Scopus* rankings and positioned at the 47th percentile in its field, the journal showcases innovative studies, clinical insights, and evidence-based practices crucial for professionals, researchers, and students alike. Although operating as a traditional publication, it seeks to provide immediate access to groundbreaking research on the prevention and management of COPD, facilitating improved patient outcomes. As it continues to expand its influence since its convergence in 2018, this journal is dedicated to bridging gaps in pulmonary medicine, making it an indispensable resource for the global respiratory health community.

ANNALS OF INTERNAL MEDICINE, published by the American College of Physicians, stands as one of the leading journals in the field of internal medicine, with an impressive impact factor that underscores its significance in academic discourse. Since its inception in 1945, this esteemed journal has maintained a steadfast commitment to publishing high-quality research that spans a broad spectrum of internal medicine, making substantial contributions to clinical practice and health policy. With a current ranking of #5 out of 167 in the field of Internal Medicine and a remarkable 97th percentile ranking in literature, the ANNALS OF INTERNAL MEDICINE is recognized as a vital resource for researchers, healthcare professionals, and students alike. Although it operates under a traditional subscription model, the journal continually emphasizes the importance of disseminating robust clinical trials, systematic reviews, and expert commentaries that advance medical knowledge and practice. Its quartile rankings in Q1 for both Internal Medicine and Miscellaneous Medicine highlight its role in shaping the future of healthcare through rigorous and impactful scientific inquiry.

Clinical Hypertension is a premier journal dedicated to advancing the field of hypertension and cardiovascular health, published by SpringerNature. Since its transition to an Open Access model in 2014, the journal has opened doors for researchers globally to share their findings without barriers, aiming to foster collaboration and innovation in this vital area of medicine. With a current impact factor that positions it in the Q2 quartile for both Cardiology and Cardiovascular Medicine and Internal Medicine, Clinical Hypertension is recognized for its scholarly contributions, reflected in its Scopus rankings (Rank #100/387 in Cardiology and Rank #52/167 in Internal Medicine), which place it in the top percentiles of these competitive fields. Covering a diverse range of topics within hypertension research, it serves as an essential resource for clinicians, researchers, and students alike, promising to keep its audience informed of the latest developments and breakthroughs from its inception in 2017 through to 2024.

BMJ Open Diabetes Research & Care is a premier open access journal published by the BMJ PUBLISHING GROUP, dedicated to advancing the field of diabetes research and care. With an impressive impact factor and positioned in the Q1 category of Endocrinology, Diabetes and Metabolism, this journal serves as a vital resource for researchers, clinicians, and healthcare professionals striving to improve diabetes management and treatment strategies. Since its inception in 2014, the journal has provided an accessible platform for high-quality, peer-reviewed research, ensuring global outreach and dissemination of groundbreaking findings in diabetes care. With Scopus ranking it at #35 out of 244 in its field, reflecting an 85th percentile ranking, BMJ Open Diabetes Research & Care remains committed to fostering innovation and discourse within the diabetes community. This journal not only publishes original research articles but also invites systematic reviews, clinical studies, and comprehensive reviews, aiming to address the pressing challenges faced in diabetes care today.

Cardiology in Review, published by Lippincott Williams & Wilkins, is a prominent journal focused on advancing the field of cardiology and cardiovascular medicine. With a history of publication spanning from 1995 to 2024, the journal serves as an essential resource for researchers, healthcare professionals, and students alike, offering in-depth reviews and analyses on the latest developments, clinical practices, and research findings in cardiology. Despite being a traditional print journal, it maintains a commendable Q2 ranking in both cardiology and miscellaneous medicine categories as of 2023, reflecting its influence and rigor in the academic community, with a Scopus rank of #132 out of 387 in its field, placing it in the 66th percentile. The journal aims to bridge the gap between clinical practice and emerging research, promoting a deeper understanding and integration of innovative strategies in cardiovascular care. With its commitment to high-quality scholarship, Cardiology in Review remains a vital conduit for knowledge and dialogue within the evolving landscape of cardiovascular health.

JOURNAL OF HYPERTENSION, published by Lippincott Williams & Wilkins, stands at the forefront of cardiovascular research, serving as a premier platform for the dissemination of knowledge in hypertension and related cardiovascular conditions. With an impressive impact factor, this esteemed journal is recognized in Q1 quartile across multiple categories, including Cardiology, Internal Medicine, and Physiology as of 2023, firmly establishing its significance within the academic community. The journal has been a reliable source of cutting-edge research since its inception in 1983, with continued publication through 2024. Researchers can expect a rigorous peer-review process and a diverse array of articles that include original research, reviews, and clinical studies aimed at enhancing the understanding and management of hypertension. Although it is not an open-access journal, the JOURNAL OF HYPERTENSION remains invaluable to clinicians, researchers, and students dedicated to advancing the field of cardiovascular health.

Kidney Diseases is an esteemed open-access journal published by KARGER that has been at the forefront of nephrology research since its inception in 2015. With an impressive Scopus ranking of #13 out of 81 in the field of Medicine Nephrology, placing it in the top 84th percentile, the journal has established itself as a vital resource for researchers, clinicians, and students interested in advancing knowledge on kidney health, disorders, and innovative treatment strategies. This journal aims to disseminate cutting-edge findings and clinical insights over a converged publication span from 2019 to 2024, fostering global collaboration and dialogue within the scientific community. With its commitment to open access, Kidney Diseases ensures that critical research is freely accessible, promoting wider dissemination of knowledge and the development of effective therapeutic interventions.

Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.